CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
University of Pennsylvania researchers have found a promising new treatment for periodontitis using a component of the immune system called complement, according to a new study in the Journal of ...
The fact that the complement system is activated during immune-complex glomerular disease has been known for nearly 50 years. Detection of complement deposition in the glomerulus using immunochemistry ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
A new analysis of lung epithelial cells from COVID-19 patients reveals how the protective complement branch of the immune system, which usually plays roles in both innate and adaptive immunity, can ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results